The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. (Q46594720)

From Wikidata

Jump to navigation Jump to search

scientific article published in March 2012

Language	Label	Description	Also known as
English	The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.	scientific article published in March 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

acute decompensated heart failure

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

14

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Beth A. Davison

17

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

18

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Christopher M O'Connor

24

object named as

Christopher M O'Connor

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

Piotr Ponikowski

15

object named as

Piotr Ponikowski

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

John R Teerlink

1

object named as

John R Teerlink

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Adriaan A Voors

16

object named as

Adriaan A Voors

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Michael M Givertz

13

object named as

Michael M Givertz

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Barry M. Massie

25

object named as

Barry M Massie

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Howard C Dittrich

23

object named as

Howard Dittrich

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

8

object named as

Ileana L Piña

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

11

object named as

Michael R Zile

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

George A. Mansoor

22

object named as

George A Mansoor

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Paul J Hauptman

5

object named as

Paul J Hauptman

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Christina M Salerno

21

object named as

Christina M Salerno

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

3

object named as

Jay P Mohr

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

author name string

Vicente J Iragui

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Peter E Carson

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

David H Lovett

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Alan B Miller

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Scott Thomson

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Paul D Varosy

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Denise Wolko

19

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Paul Delucca

20

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

publication date

1 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

35

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

233-244

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

A1 adenosine receptor antagonists, agonists, and allosteric enhancers

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies.

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment e

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

The pilot Stroke Data Bank: definition, design, and data

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE.

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

The adenosine kinase hypothesis of epileptogenesis

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

What can adenosine neuromodulation do for neuroprotection?

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Antithrombotic therapy for cerebrovascular disorders. An update

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS).

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Intracerebral adenosine infusion improves neurological outcome after transient focal ischemia in rats

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

The role of intracellular 3'5'-cyclic adenosine monophosphate (cAMP) in atherosclerosis.

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Adenosine receptors and the central nervous system.

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Adenosine receptors and neurological disease: neuroprotection and neurodegeneration

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/22339573

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11594680-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46594720&oldid=2207966990"